Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma

BACKGROUND/AIMS: Sorafenib remains the only approved molecular targeted agent for hepatocellular carcinoma (HCC); however, reliable biomarkers that predict its efficacy are still lacking. The aim of this study was to explore whether cancer stem cell (CSC) markers have a predictive role with regard t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Bo Hyun, Park, Joong-Won, Kim, Jin Sook, Lee, Sook-Kyung, Hong, Eun Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529171/
https://www.ncbi.nlm.nih.gov/pubmed/30600675
http://dx.doi.org/10.5009/gnl18345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529171/
https://www.ncbi.nlm.nih.gov/pubmed/30600675
http://dx.doi.org/10.5009/gnl18345

Ejemplares similares